<DOC>
	<DOCNO>NCT02740829</DOCNO>
	<brief_summary>Peripheral glucagon action increase hepatic glucose production . In rodent hypothalamic action glucagon paradoxically suppress glucose production . Intranasally administer peptide show preferentially enter central nervous system . We assess effect intranasal glucagon hepatic glucose production</brief_summary>
	<brief_title>Assessment Intranasal Glucagon Endogenous Glucose Production</brief_title>
	<detailed_description>Fifteen healthy , lean , non-diabetic male female undergo two study ( single blind crossover ) , random order , 4-6 week apart . Study A. Intranasal placebo administration measurement endogenous glucose production pancreatic clamp condition . Study B. Intranasal glucagon ( glucagon , Eli Lilly , Canada ) administration measurement endogenous glucose production pancreatic clamp condition Each study participant admit Metabolic Test Centre Toronto General Hospital day study 12pm . They provide standardized dinner ( consist 7 Kcal/kg ; 50 % carbohydrate , 30 % fat , 20 % protein ) require fast 12 hr overnight ( water food drink ) . At 7am ( t=0 ) next day , begin prim , constant intravenous infusion [ 6,6-2H2 ] glucose ( D2 glucose ; Cambridge Isotope Laboratories , MA ; stable isotope glucose , enrichment measure GC/MS , allow u calculate endogenous glucose production rate ) . The infusion continue 8 hour . At time ( 7am ) pancreatic clamp start 8 hour order suppress pancreatic hormone secretion somatostatin provide basal infusion pancreatic hormone growth hormone intravenous infusion . This method permit u study effect intranasal glucagon hepatic glucose TRL production without confound effect may pancreatic hormone secretion . A simultaneous infusion somatostatin ( Sandostatin , Novartis Pharma , Miss , ON 30mcg/hr ) , insulin ( Humulin R , Eli Lilly , Scarborough , ON , 0.05mU/kg/min ) , glucagon ( Eli Lilly , Miss , ON 0.325ng/kg/min ) growth hormone ( Humatrope , Eli Lilly , Mississauga , ON 3ng/kg/min ) start continue throughout study . All hormone dilute 1 liter normal saline infuse syringe pump ( B. Braun Medical Inc. , Bethlehem , PA ) . Autologous serum ( 3 mL ) , freshly prepared subject 's blood , add saline carrier prior hormone dilution . A study nurse and/or doctor bedside throughout clamp monitoring participant 's blood glucose every 30 minute onset clamp every 10 minute administration glucagon ( clinically indicate , sample may frequent ) ensure participant develop hypo/hyperglycemia . Blood sample analyse glucometer instant blood glucose reading . If intranasal glucagon reduces endogenous glucose production , reduction plasma glucose likely . 20 % dextrose administer necessary maintain euglycemia At 9 ( +120 minute ) intranasal placebo glucagon administer . The glucagon ( Eli Lily , Canada ) placebo ( diluent ) transfer meter nasal device ( Pharmasystems , Markham , Ontario UPC : 063636 802721 , Item 10271 ) immediately prior use . This device dispense 0.1ml ( 0.1mg ) per puff . A maximum 15 X0.1 ml puffs/vials ( 7 1 nostril 8 nostril ) administer rate 2 ( one nostril ) every 60 second . This dose may titrate necessary reduce peripheral spillover . Blood sample collect every 30 minute start clamp every 10 minute administration intranasal glucagon placebo ( total 400 ml ) . The blood sample collect chill sterile tube contain 0.1 % EDTA preservative ( aprotinin , sodium azide ) process indicate . In order match peripheral glucagon concentration study visit , small dose glucagon likely need administer intravenously 9am , placebo arm study . Based pharmacokinetics glucagon , likely administer 0.00625mg-0.025mg , although dose titration may necessary ( maximum dose 0.1mg ) . Free fatty acid , triglyceride , insulin , glucagon , C-peptide , glucagon-like peptide-1 ( GLP-1 ) GIP , well glucose isotopic enrichment measure .</detailed_description>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Men woman , age 18 60 year 2 . Body mass index 20 27 kg/m2 3 . Hemoglobin normal range . 4 . Normal glucose tolerance response 75gram glucose 1 . Study participant history hepatitis/hepatic disease active within previous two year . 2 . Any current previous history biliary disease ( include gall stone , biliary atresia cholecystitis ) pancreatitis . 3 . Any current previous history endocrine disease , dyslipidemia malignancy 4 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal , genitourinary , hematological system , severe uncontrolled treated untreated hyper/ hypotension ( sit diastolic &gt; 100 systolic &gt; 180 systolic &lt; 100 ) proliferative retinopathy 5 . Use immunosuppressive agent time study 6 . Allergy study medication 7 . Pregnancy breastfeed 8 . Heavy smoker 9 . Fasting blood glucose &gt; 6.0 mmol/l know diabetes . 10 . Any history MI clinically significant , active , cardiovascular history include history arrhythmia 's conduction delay ECG , unstable angina , decompensated heart failure . 11 . Any nasal pathology . 12 . Abnormal liver thyroid function 13 . Current addiction alcohol substance abuse determine investigator mental illness . 14 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 15 . Taking regular prescription nonprescription medication time study . Occasional use medication acetoaminophen Tylenol 1 use natural health product may permit discretion investigator . 16 . Will donate blood three month prior three month post study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>